Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Curex vs Eden

Both scored on the same six-factor Match Score. Eden wins this matchup with a 87 to 86 edge — a photo finish.

Curex

#8 · Grade B+

People who value a transparent, well-supported program with simple same-price-either-molecule billing.

Visit Curex
VS
Higher Match Score

Eden

#4 · Grade B+

People who prioritize a vetted, high-transparency, high-touch provider over the lowest sticker price.

Visit Eden

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
80
74
Speed to Start
88
90
Formulary Match
86
80
Support Level
88
94
Flexibility
86
90
Transparency
88
92

Price, coverage & formulary

DetailCurexEden
Semaglutide$199/mo$239/mo
Tirzepatide$199/mo$349/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjectable only
Match Score86 · B+87 · B+
Winner: Eden

Eden edges out Curex, 87 to 86 on the default Match Score. A polished, high-disclosure compounded program with strong nationwide coverage and hands-on support.

Curex is still a fair pick if its strengths line up with yours — best for: People who value a transparent, well-supported program with simple same-price-either-molecule billing.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Curex reviewFull Eden review

More head-to-heads

Or browse alternatives to Eden and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.